EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study

Tinei Shamu iD, Matthias Egger, Tinashe Mudzviti, Cleophas Chimbetete, Justen Manasa, Nanina Anderegg iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0293162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Tinei Shamu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Newlands Clinic, Harare, Zimbabwe. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Piperazines, Pyridones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, NIAID NIH HHS, Fogarty International Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are few data from sub-Saharan Africa on the virological outcomes associated with second-line ART based on protease inhibitors or dolutegravir (DTG). We compared viral load (VL) suppression among people living with HIV (PLWH) on atazanavir (ATV/r)- or DTG-based second-line ART with PLWH on efavirenz (EFV)-based first-line ART. We analyzed data from the electronic medical records system of Newlands Clinic in Harare, Zimbabwe. We included individuals aged ≥12 years when commencing first-line EFV-based ART or switching to second-line DTG- or ATV/r-based ART with ≥24 weeks follow-up after start or switch. We computed suppression rates (HIV VL

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsPiperazinesPyridonesAlkynesOxazinesHeterocyclic Compounds, 3-RingCyclopropanesHumansFemaleMaleAtazanavir SulfateLongitudinal StudiesZimbabweBayes TheoremBenzoxazinesViral LoadDolutegravir

Substanzen

Anti-HIV AgentsAtazanavir SulfateBenzoxazinesPiperazinesPyridonesAlkynesOxazinesHeterocyclic Compounds, 3-RingCyclopropanesDolutegravir

Autor:innen und Institutionen

  • Newlands Clinic, Harare, Zimbabwe.
  • Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Graduate School of Health Sciences, University of Bern, Bern, Switzerland.
  • Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa.
  • Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare, Zimbabwe.

ORCID-Profile: Tinei Shamu, Nanina Anderegg

Förderung

  • FIC NIH HHS
  • NIAID NIH HHS
  • Fogarty International Center
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Shamu, T., Egger, M., Mudzviti, T., Chimbetete, C., Manasa, J., & Anderegg, N. (2024). Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study. PLOS ONE. https://doi.org/10.1371/journal.pone.0293162

Vancouver

Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study. PLOS ONE. 2024. doi:10.1371/journal.pone.0293162

BibTeX
@article{Shamu2024,
  author = {Shamu, Tinei and Egger, Matthias and Mudzviti, Tinashe and Chimbetete, Cleophas and Manasa, Justen and Anderegg, Nanina},
  title = {Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0293162}
}
Kostenlos starten →